Document:

arav-ex104_53.htm

Exhibit 10.4

AGREEMENT

THIS AGREEMENT (the “Agreement”) dated as of April 8, 2020, is between Aravive, Inc., a Delaware corporation (the “Company”), and Srinivas Akkaraju, a non-employee director of the Company (the “Participant”). Capitalized terms used herein without definition shall have the meaning ascribed such terms in the 2014 Equity Incentive Plan and the 2019 Equity Incentive Plan (the “Plans”).

WHEREAS, the Participant is the holder of the Options set forth on the annexed Schedule A issued under the Company’s 2014 Equity Incentive Plan and the 2019 Equity Incentive Plan (herein, together, the “Options”, and individually, any “Option”); and

WHEREAS, the Company and the Participant desire to amend all of the Options held by the Participant to provide that, to the extent vested, such Options shall remain outstanding and exercisable following the Participant’s resignation as a director (the “Resignation Date”) until the earlier of (a) the one year anniversary of the Resignation Date, and (b) the end of the Term as set forth in the written agreement between the Company and Participant evidencing the terms of the Options (the “Award Agreements”) .

WHEREAS, the Company and the Participant desire to amend the Option included in Schedule A to purchase 7,500 shares of common stock of the Company granted to the Participant on September 12, 2019 under the 2019 Equity Incentive Plan to provide that, vesting of such Option shall be accelerated such that the Option shall be fully vested on the Resignation Date.

NOW, THEREFORE, in consideration of the premises and the mutual covenants hereinafter set forth and for other good and valuable consideration, receipt and sufficiency of which is hereby acknowledged, the parties hereto have agreed, and do hereby agree, as follows:

1.  Option Exercise Extension. Effective as of the date hereof, notwithstanding anything to the contrary set forth in the Plans or any Award Agreement, immediately upon the Participant’s resignation as a director, any Option which is vested at the time of such resignation (including the Option to purchase 7,500 shares of common stock of the Company issued September 12, 2019 under the 2019 Equity Incentive Plan) shall remain exercisable (in accordance with the requirements of the respective Plans), until the earlier of (a) the one year anniversary of the Resignation Date, and (b) the end of the applicable Term as set forth in the applicable Award Agreement. This Section 1 shall amend any term to the contrary contained in the Plans and any Award Agreement of the Participant under the Plans outstanding on the date hereof. 

2.  Acceleration of Vesting. Effective as of the date hereof, notwithstanding anything to the contrary in the Plans or any Award Agreement, immediately upon the Participant’s resignation as a director, vesting of the Option to purchase 7,500 shares of common stock of the Company granted to Participant on September 12, 2019 under the 2019 Equity Incentive Plan shall be accelerated such that the Option shall be fully vested on the Resignation Date. This Section 2 shall amend any term to the contrary contained in the 2019 Equity Incentive Plan and any Award Agreement of the Participant under the 2019 Equity Incentive Plan outstanding on the date hereof. 

3. Non-Disparagement.  Participant agrees not to disparage the Company or the Company’s officers, directors, employees, shareholders (in their capacities as shareholders of the Company), parents, subsidiaries, affiliates, and agents (in their capacities as agents of the Company), in any manner likely to be harmful to them or their business, business reputation, or personal reputation and Participant is not aware of any basis for any legal claims against the Company, its officers, directors, employees, shareholders (in their capacities as shareholders of the Company), parents, subsidiaries, affiliates, or agents (in their capacities as agents of the Company) relating to such matters. The Company agrees, and 

agrees to direct its officers and directors, not to disparage Participant in any manner likely to be harmful to Participant’s business, business reputation or personal reputation and the Company and its officers and directors are not aware of any basis for any legal claims against Participant relating to such matters.  Notwithstanding the foregoing, both Participant and the Company and its officers, directors, employees, shareholders, parents, subsidiaries, affiliates, and agents may respond accurately and fully to any question, inquiry, or request for information when required by legal process or in connection with a government investigation. In addition, nothing in this provision or this Agreement is intended to prohibit or restrain Participant in any manner from making disclosures that are protected under the whistleblower provisions of federal or law or regulation.  

4. Treatment of Confidential Information and Trading of Common Stock.  Participant acknowledges and agrees that Participant has a fiduciary duty and obligation to maintain the confidentiality of any confidential information of the Company disclosed to Participant or learned by Participant as a director of the Company or otherwise.  Participant acknowledges that Participant may not trade in the Company’s common stock while Participant is in possession of material non-public information or while Participant is subject to any blackouts contained in the Company’s insider trading policy.

5. Indemnification Agreement.  The Company hereby acknowledges and affirms its obligations pursuant to that certain indemnification agreement between the Company and Participant dated December 7, 2016 (the “Indemnification Agreement”). 

6.  Governing Law. This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware (other than its laws respecting choice of law).

7. Entire Agreement. This Agreement, the Indemnification Agreement and the Options constitute the entire obligation of the parties hereto with respect to the subject matter hereof and shall supersede any prior expressions of intent or understanding with respect to this matter.

8.  Amendment. Any amendment to this Agreement shall be in writing and signed by the Company and the Participant.

9.  Waiver; Cumulative Rights. The failure or delay of either party to require performance by the other party of any provision hereof shall not affect its right to require performance of such provision unless and until such performance has been waived in writing. Each and every right hereunder is cumulative and may be exercised in part or in whole from time to time.

 

10.  Counterparts. This Agreement may be signed in two counterparts, each of which shall be an original, but both of which shall constitute but one and the same instrument.

11.  Headings. The headings contained in this Agreement are for reference purposes only and shall not affect the meaning or interpretation of this Agreement.

12.  Successors and Assigns. This Agreement shall inure to the benefit of and be binding upon each successor and assign of the Company. All obligations imposed on the Participant, and all rights granted to the Company hereunder, shall be binding upon the Participant’s heirs, legal representatives and successors.

 

 

 

 

IN WITNESS WHEREOF, the Company has caused this Agreement to be duly executed by an officer thereunto duly authorized, and the Participant has hereunto set his or her hand, all as of the day and year first above written.

 

	
 
	
 
	
 

	
ARAVIVE, INC.

	
 
	
 

	
By:
	
 
	
 /s/ Vinay Shah          

	
 
	
 
	
Vinay Shah

	
 
	
 
	
Chief Financial Officer

	
 

	
PARTICIPANT:

	
 
	
 

	
By:
	
 
	
 /s/ Srinivas Akkaraju

	
Name: 
	
 
	
Srinivas Akkaraju

	
 
	
 
	
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Schedule A

 

	
Name
	
 
	
Grant

Number
	
 
	
Grant

Date
	
 
	
Plan/Type
	
 
	
Grant

Shares
	
 
	
Price
	
 
	
Exercised/

Released
	
 
	
Vested
	
 
	
Unvested
	
 
	
Outstanding/

Unreleased
	
 
	
Exercisable/

Releasable

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
Akkaraju, Srinivas
	
 
	
000546
	
 
	
06/29/2015
	
 
	
2014/NQ
	
 
	
2,183
	
 
	
$88.380
	
 
	
0
	
 
	
2,183
	
 
	
0
	
 
	
2,183
	
 
	
2,183

	
 
	
 
	
000552
	
 
	
06/29/2015
	
 
	
2014/RSU
	
 
	
762
	
 
	
$0.000
	
 
	
762
	
 
	
762
	
 
	
0
	
 
	
0
	
 
	
0

	
 
	
 
	
000670
	
 
	
06/14/2016
	
 
	
2014/RSU
	
 
	
1,150
	
 
	
$0.000
	
 
	
1,150
	
 
	
1,150
	
 
	
0
	
 
	
0
	
 
	
0

	
 
	
 
	
000671
	
 
	
06/14/2016
	
 
	
2014/NQ
	
 
	
4,786
	
 
	
$65.220
	
 
	
0
	
 
	
4,786
	
 
	
0
	
 
	
4,786
	
 
	
4,786

	
 
	
 
	
000672
	
 
	
03/21/2014
	
 
	
2014/NQ
	
 
	
3,159
	
 
	
$126.000
	
 
	
0
	
 
	
3,159
	
 
	
0
	
 
	
3,159
	
 
	
3,159

	
 
	
 
	
000832
	
 
	
05/25/2017
	
 
	
2014/RSU
	
 
	
580
	
 
	
$0.000
	
 
	
580
	
 
	
580
	
 
	
0
	
 
	
0
	
 
	
0

	
 
	
 
	
000840
	
 
	
05/25/2017
	
 
	
2014/NQ
	
 
	
1,141
	
 
	
$94.950
	
 
	
0
	
 
	
1,141
	
 
	
0
	
 
	
1,141
	
 
	
1,141

	
 
	
 
	
000903
	
 
	
12/20/2017
	
 
	
2014/RSU
	
 
	
1,866
	
 
	
$0.000
	
 
	
1,866
	
 
	
1,866
	
 
	
0
	
 
	
0
	
 
	
0

	
 
	
 
	
AR000074
	
 
	
01/03/2019
	
 
	
2014/NQ
	
 
	
4,688
	
 
	
$3.610
	
 
	
0
	
 
	
4,688
	
 
	
0
	
 
	
4,688
	
 
	
4,688

	
 
	
 
	
AR000090
	
 
	
09/12/2019
	
 
	
2019/NQ
	
 
	
7,500
	
 
	
$5.770
	
 
	
0
	
 
	
3,750
	
 
	
3,750
	
 
	
7,500
	
 
	
3,750

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
27,815
	
 
	
 
	
 
	
4,358
	
 
	
24,065
	
 
	
3,750
	
 
	
23,457
	
 
	
19,707arav-ex105_52.htm

Exhibit 10.5

AGREEMENT

THIS AGREEMENT (the “Agreement”) dated as of April 8, 2020, is between Aravive, Inc., a Delaware corporation (the “Company”), and Jay Shepard, a non-employee director of the Company (the “Participant”). Capitalized terms used herein without definition shall have the meaning ascribed such terms in the 2014 Equity Incentive Plan and the 2019 Equity Incentive Plan (the “Plans”).

WHEREAS, the Participant is the holder of the Options (the “Options”) and Restricted Stock Units (“RSUs”) set forth on the annexed Schedule A issued under the Company’s 2014 Equity Incentive Plan and the 2019 Equity Incentive Plan; and

WHEREAS, the Company and the Participant desire to amend all of the Options held by the Participant to provide that, to the extent vested, such Options shall remain outstanding and exercisable following the Participant’s resignation as a director (the “Resignation Date”) until the earlier of (a) the one year anniversary of the Resignation Date, and (b) the end of the Term as set forth in the written agreement between the Company and Participant evidencing the terms of the Options (the “Award Agreements”) .

WHEREAS, the Company and the Participant desire to amend the Options and RSUs included in Schedule A to purchase  shares of common stock of the Company granted to the Participant  under the 2014 Equity Incentive Plan and the 2019 Equity Incentive Plan to provide that, vesting of such Options and RSUs shall be accelerated such that the unvested portion of the outstanding Options and RSUs that would have otherwise vested on the twelve month anniversary of the Resignation Date if Participant had remained a director for such twelve months shall be fully vested on the Resignation Date.

NOW, THEREFORE, in consideration of the premises and the mutual covenants hereinafter set forth and for other good and valuable consideration, receipt and sufficiency of which is hereby acknowledged, the parties hereto have agreed, and do hereby agree, as follows:

1.  Option Exercise Extension. Effective as of the date hereof, notwithstanding anything to the contrary set forth in the Plans or any Award Agreement, immediately upon the Participant’s resignation as a director, any Option which is vested at the time of such resignation (including the Option to purchase 7,500 shares of common stock of the Company issued September 12, 2019 under the 2019 Equity Incentive Plan) shall remain exercisable (in accordance with the requirements of the respective Plans), until the earlier of (a) the one year anniversary of the Resignation Date, and (b) the end of the applicable Term as set forth in the applicable Award Agreement. This Section 1 shall amend any term to the contrary contained in the Plans and any Award Agreement of the Participant under the Plans outstanding on the date hereof. 

2.  Acceleration of Vesting. Effective as of the date hereof, notwithstanding anything to the contrary in the Plans or any Award Agreement, immediately upon the Participant’s resignation as a director, the unvested portion of the outstanding Options and RSUs that would have otherwise vested on the twelve month anniversary of the Resignation Date if Participant had remained a director for such twelve months shall be accelerated and fully vested on the Resignation Date. This Section 2 shall amend any term to the contrary contained in the 2014 Equity Incentive Plan and the 2019 Equity Incentive Plan and any Award Agreement of the Participant under the 2014 Equity Incentive Plan and the 2019 Equity Incentive Plan outstanding on the date hereof. 

3.  Non-Disparagement.  Participant agrees not to disparage the Company or the Company’s officers, directors, employees, shareholders (in their capacities as shareholders of the Company), parents, subsidiaries, affiliates, and agents (in their capacities as agents of the Company, in any manner likely to be harmful to them or their business, business reputation, or personal reputation and Participant is not 

aware of any basis for any legal claims against the Company, its officers, directors, employees, shareholders (in their capacities as shareholders of the Company), parents, subsidiaries, affiliates, or agents (in their capacities as agents of the Company) relating to such matters. The Company agrees, and agrees to direct its officers and directors, not to disparage Participant in any manner likely to be harmful to Participant’s business, business reputation or personal reputation and the Company and its officers and directors are not aware of any basis for any legal claims against Participant relating to such matters..  Notwithstanding the foregoing, both Participant and the Company and its officers, directors, employees, shareholders, parents, subsidiaries, affiliates, and agents may respond accurately and fully to any question, inquiry, or request for information when required by legal process or in connection with a government investigation. In addition, nothing in this provision or this Agreement is intended to prohibit or restrain Participant in any manner from making disclosures that are protected under the whistleblower provisions of federal or law or regulation.  

4.  Treatment of Confidential Information and Trading of Common Stock.  Participant acknowledges and agrees that Participant has a fiduciary duty and obligation to maintain the confidentiality of any confidential information of the Company disclosed to Participant or learned by Participant as a director of the Company or otherwise.  Participant acknowledges that Participant may not trade in the Company’s common stock while Participant is in possession of material non-public information or while Participant is subject to any blackouts contained in the Company’s insider trading policy.

5.  Indemnification Agreement.  The Company hereby acknowledges and affirms its obligations pursuant to that certain indemnification agreement between the Company and Participant dated December 7, 2016 (the “Indemnification Agreement”). 

6.  Governing Law. This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware (other than its laws respecting choice of law).

7.  Entire Agreement. This Agreement, the Indemnification Agreement and the Options constitute the entire obligation of the parties hereto with respect to the subject matter hereof and shall supersede any prior expressions of intent or understanding with respect to this matter.

8.  Amendment. Any amendment to this Agreement shall be in writing and signed by the Company and the Participant.

9.  Waiver; Cumulative Rights. The failure or delay of either party to require performance by the other party of any provision hereof shall not affect its right to require performance of such provision unless and until such performance has been waived in writing. Each and every right hereunder is cumulative and may be exercised in part or in whole from time to time.

 

10.  Counterparts. This Agreement may be signed in two counterparts, each of which shall be an original, but both of which shall constitute but one and the same instrument.

11.  Headings. The headings contained in this Agreement are for reference purposes only and shall not affect the meaning or interpretation of this Agreement.

12.  Successors and Assigns. This Agreement shall inure to the benefit of and be binding upon each successor and assign of the Company. All obligations imposed on the Participant, and all rights granted to the Company hereunder, shall be binding upon the Participant’s heirs, legal representatives and successors.

IN WITNESS WHEREOF, the Company has caused this Agreement to be duly executed by an officer thereunto duly authorized, and the Participant has hereunto set his or her hand, all as of the day and year first above written.

 

	
 
	
 
	
 

	
ARAVIVE, INC.

	
 
	
 

	
By:
	
 
	
  /s/ Vinay Shah          

	
 
	
 
	
Vinay Shah

	
 
	
 
	
Chief Financial Officer

	
 

	
PARTICIPANT:

	
 
	
 

	
By:
	
 
	
  /s/ Jay Shepard

	
Name: 
	
 
	
Jay Shepard

	
 
	
 
	
 

 

Schedule A

 

	
Name
	
 
	
Grant

Number
	
 
	
Grant

Date
	
 
	
Plan/Type
	
 
	
Grant

Shares
	
 
	
Price
	
 
	
Exercised/

Released
	
 
	
Vested
	
 
	
Unvested
	
 
	
Outstanding/

Unreleased
	
 
	
Exercisable/

Releasable

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
Shepard, Jay
	
 
	
000543
	
 
	
05/11/2015
	
 
	
2014/NQ
	
 
	
51,500
	
 
	
$91.14
	
 
	
0
	
 
	
51,500
	
 
	
0
	
 
	
51,500
	
 
	
51,500

	
 
	
 
	
000544
	
 
	
05/11/2015
	
 
	
2014/RSU
	
 
	
16,000
	
 
	
$0.00
	
 
	
16,000
	
 
	
16,000
	
 
	
0
	
 
	
0
	
 
	
0

	
 
	
 
	
000601
	
 
	
01/28/2016
	
 
	
2014/NQ
	
 
	
34,866
	
 
	
$64.08
	
 
	
0
	
 
	
34,866
	
 
	
0
	
 
	
34,866
	
 
	
34,866

	
 
	
 
	
000609
	
 
	
01/28/2016
	
 
	
2014/RSU
	
 
	
10,800
	
 
	
$0.00
	
 
	
10,800
	
 
	
10,800
	
 
	
0
	
 
	
0
	
 
	
0

	
 
	
 
	
000697
	
 
	
01/27/2017
	
 
	
2014/RSU
	
 
	
1,666
	
 
	
$0.00
	
 
	
1,666
	
 
	
1,666
	
 
	
0
	
 
	
0
	
 
	
0

	
 
	
 
	
000699
	
 
	
01/27/2017
	
 
	
2014/RSU
	
 
	
10,783
	
 
	
$0.00
	
 
	
8,087
	
 
	
8,087
	
 
	
2,696
	
 
	
2,696
	
 
	
0

	
 
	
 
	
000763
	
 
	
01/27/2017
	
 
	
2014/NQ
	
 
	
24,150
	
 
	
$85.80
	
 
	
0
	
 
	
19,118
	
 
	
5,032
	
 
	
24,150
	
 
	
19,118

	
 
	
 
	
000883
	
 
	
10/06/2017
	
 
	
2014/RSU
	
 
	
31,500
	
 
	
$0.00
	
 
	
31,500
	
 
	
31,500
	
 
	
0
	
 
	
0
	
 
	
0

	
 
	
 
	
000910
	
 
	
12/20/2017
	
 
	
2014/RSU
	
 
	
37,166
	
 
	
$0.00
	
 
	
18,584
	
 
	
18,584
	
 
	
18,582
	
 
	
18,582
	
 
	
0

	
 
	
 
	
147
	
 
	
12/28/2013
	
 
	
2009/NQ
	
 
	
2,177
	
 
	
$15.18
	
 
	
0
	
 
	
2,177
	
 
	
0
	
 
	
2,177
	
 
	
2,177

	
 
	
 
	
150
	
 
	
12/28/2013
	
 
	
2009/NQ
	
 
	
19,832
	
 
	
$15.18
	
 
	
8,861
	
 
	
19,832
	
 
	
0
	
 
	
10,971
	
 
	
10,971

	
 
	
 
	
161
	
 
	
02/19/2014
	
 
	
2009/NQ
	
 
	
7,563
	
 
	
$48.99
	
 
	
0
	
 
	
7,563
	
 
	
0
	
 
	
7,563
	
 
	
7,563

	
 
	
 
	
AR000084
	
 
	
02/28/2019
	
 
	
2014/ISO
	
 
	
73,442
	
 
	
$5.83
	
 
	
0
	
 
	
21,440
	
 
	
52,002
	
 
	
73,442
	
 
	
21,440

	
 
	
 
	
AR000085
	
 
	
02/28/2019
	
 
	
2014/NQ
	
 
	
42,558
	
 
	
$5.83
	
 
	
0
	
 
	
9,976
	
 
	
32,582
	
 
	
42,558
	
 
	
9,976

	
 
	
 
	
AR000094
	
 
	
01/09/2020
	
 
	
2019/NQ
	
 
	
5,075
	
 
	
$13.77
	
 
	
0
	
 
	
1,268
	
 
	
3,807
	
 
	
5,075
	
 
	
1,268

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
369,078
	
 
	
 
	
 
	
95,498
	
 
	
254,377
	
 
	
114,701
	
 
	
273,580
	
 
	
158,879

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00307-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00307-of-00352.parquet"}]]